Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials

Affiliations

¹ Department of Anesthesiology, Division of Pain Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.
² Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
³ Johns Hopkins School of Medicine, Baltimore, MD.
⁴ Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
⁵ Department of Anesthesiology, Creighton University School of Medicine, Omaha, NE; Valley Anesthesiology and Pain Consultants, Envision Physician Services, Phoenix, AZ; and Department of Anesthesiology, University of Arizona College of Medicine-Phoenix, Phoenix, AZ.

Editorial

Alaa A Abd-Elsayed et al. Ochsner J. 2020 Winter.

. 2020 Winter;20(4):350-357.

doi: 10.31486/toj.20.0124.

¹ Department of Anesthesiology, Division of Pain Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.
² Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
³ Johns Hopkins School of Medicine, Baltimore, MD.
⁴ Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
⁵ Department of Anesthesiology, Creighton University School of Medicine, Omaha, NE; Valley Anesthesiology and Pain Consultants, Envision Physician Services, Phoenix, AZ; and Department of Anesthesiology, University of Arizona College of Medicine-Phoenix, Phoenix, AZ.

No abstract available

References

1. Gautret P, Lagier JC, Parola P, et al. . Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949 - DOI - PMC - PubMed
1. Rosendaal FR. Review of: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949. Int J Antimicrob Agents. 2020;56(1):106063. doi: 10.1016/j.ijantimicag.2020.106063 - DOI - PMC - PubMed
1. Voss A, Coombs G, Unal S, Saginur R, Hsueh PR. Publishing in face of the COVID-19 pandemic. Int J Antimicrob Agents. 2020;56(1):106081. doi: 10.1016/j.ijantimicag.2020.106081 - DOI - PMC - PubMed
1. Chen J, Liu D, Liu L, et al. . A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19 [in Chinese]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215-219. - PMC - PubMed
1. Chen Z, Hu J, Zhang Z, et al. . Efficacy of hydroxychloroquine in patients with Covid-19: results of a randomized clinical trial. medRxiv. Preprint posted online April 10, 2020. doi: 10.1101/2020.03.22.20040758 - DOI